Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now

Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now

Source: 
Endpoints
snippet: 

Acorda has lost its last-ditch attempt to retain control of the cash cow it badly needed to sustain the company. The Supreme Court has refused to hear its argument against a lower court ruling that opened the gate to knockoffs of its multiple sclerosis drug Ampyra.